CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 10, 2013--
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the
Company will be presenting at the Stifel Nicolaus 2013 Healthcare
Conference. The presentation is scheduled for September 12, 2013 at 3:15
p.m. ET at the Four Seasons Hotel in Boston, MA.
A live audio webcast of the presentation will be available in the
Investor section of Idera's website: www.iderapharma.com.
An archived version will also be available on the Company's website
after the event for a limited time.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals technology platform involves creating novel
synthetic RNA- and DNA-based compounds to modulate immune responses.
Idera has applied this platform to develop proprietary Toll-like
receptor (TLR) antagonists as immunomodulatory drug candidates.
Toll-like receptor antagonists block the overactivation of immune
factors which can cause a range of pathological effects. Idera is
conducting clinical development of TLR antagonists in autoimmune and
inflammatory diseases, and preclinical development of their use in
certain genetically defined lymphomas. More information on Idera is
available at iderapharma.com.
Source: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com
